Difficult-to-treat rheumatoid arthritis: An area of unmet clinical need

Rheumatology (United Kingdom)

Volumn 57, Issue 7, 2018, Pages 1135-1144

  de Hair, Maria J H ^a   Jacobs, Johannes W G ^a   Schoneveld, Jan L M ^a   van Laar, Jacob M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Biological therapies; Inflammation; Pain assessment and management; Patient attitude to health; Quality of healthcare; Refractory; Rheumatoid arthritis; Synovitis; Ultrasound

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADVERSE DRUG REACTION; COMORBIDITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TREATMENT FAILURE; DRUG USE; FATIGUE; HUMAN; IMMUNOGENICITY; INFECTION; INFLAMMATORY DISEASE; INJECTION SITE REACTION; LIFESTYLE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PHARMACOGENETICS; PHYSICAL DISEASE BY BODY FUNCTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SMOKING;

EID: 85041281102     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Woodworth T, Den Broeder A. Treating to target in established rheumatoid arthritis: challenges and opportunities in an era of novel targeted therapies and biosimilars. Best Pract Res Clin Rheumatol 2015;29:543-9.
2. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
3. Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis 2006;65:227-33.
4. Nam JL, Ramiro S, Gaujoux-Viala C et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516-28.
5. Singh JA, Saag KG, Bridges SL, Jr et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.
6. Unger M, Alasti F, Supp G, Smolen JS, Aletaha D. The good, the bad and the ugly -refractory rheumatoid arthritis in 2016. Arthritis Rheumatol 2016;68(Suppl 10):Abstract No. 3015. http://acrabstracts.org/abstract/ the-good-the-bad-and-the-ugly-refractory-rheumatoidarthritis-in-2016/ (27 August 2017, date last accessed).
7. Haringman JJ, Gerlag DM, Zwinderman AH et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:834-8.
8. Wijbrandts CA, Vergunst CE, Haringman JJ et al. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007;56:3869-71.
9. Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 2009;68:1011-6.
10. Thurlings RM, Vos K, Wijbrandts CA et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008;67:917-25.
11. Chaussabel D, Quinn C, Shen J et al. A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. Immunity 2008;29:150-64.
12. Oswald M, Curran ME, Lamberth SL et al. Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders. Arthritis Rheumatol 2015;67:344-51.
13. Klaasen R, Thurlings RM, Wijbrandts CA et al. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum 2009;60:3217-24.
14. Wijbrandts CA, Dijkgraaf MG, Kraan MC et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann N Y Acad Sci 2008;67:1139-44.
15. Behrens F, Tak PP, Østergaard M et al. MOR103, a human monoclonal antibody to granulocyte-macrophage colonystimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 2015;74:1058-64.
16. Burmester GR, McInnes IB, Kremer J et al. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis 2017;13:38-45.
17. Jones DS, Jenney AP, Swantek JL et al. Profiling drugs for rheumatoid arthritis that inhibit synovial fibroblast activation. Nat Chem Biol 2017;13:38-45.
18. Martin E, O'Sullivan B, Low P, Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10 Immunity 2003;18:155-67.
19. Bell GM, Anderson AE, Diboll J et al. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis 2017;76:227-34.
20. Tuomi T, Heliovaara M, Palosuo T, Aho K. Smoking, lung function, and rheumatoid factors. Ann Rheum Dis 1990;49:753-6.
21. Klareskog L, Stolt P, Lundberg K et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLADR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38-46.
22. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 2010;34:J258-65.
23. De Rooy DP, van Nies JA, Kapetanovic MC et al. Smoking as a risk factor for the radiological severity of rheumatoid arthritis: a study on six cohorts. Ann Rheum Dis 2014;73:1384-987.
24. Westhoff G, Rau R, Zink A. Rheumatoid arthritis patients who smoke have a higher need for DMARDs and feel worse, but they do not have more joint damage than nonsmokers of the same serological group. Rheumatology 2008;47:849-54.
25. Rojas-Serrano J, Pé rez LL, García CG et al. Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. Clin Rheumatol 2011;30:1589-93.
26. Fisher MC, Hochberg MC, El-Taha M et al. Smoking, smoking cessation, and disease activity in a large cohort of patients with rheumatoid arthritis. J Rheumatol 2012;39:904-9.
27. Saevarsdottir S, Wallin H, Seddighzadeh M et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial openlabel phase of the SWEFOT trial. Ann Rheum Dis 2011;70:469-75.
28. Andersson ML, Bergman S, Soderlin MK. The effect of stopping smoking on disease activity in rheumatoid arthritis (RA). Data from BARFOT, a multicenter study of early RA. Open Rheumatol J 2012;6:303-9.
29. Van Ede AE, Laan RFJM, Blom HJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30.
30. Wessels JAM, De Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-95.
31. Li X, Hu M, Li W et al. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: a meta-analysis. Int Immunopharmacol 2016;38:8-15.
32. Chen Y, Zou K, Sun J, Yang Y, Liu G. Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. Pharmacogenomics 2017;18:175-95.
33. Cui J, Saevarsdottir S, Thomson B et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor therapy. Arthritis Rheum 2010;62:1849-61.
34. Marquez A, Ferreiro-Iglesias A, Davila-Fajardo C et al. Lack of validation of genetic variants associated with antitumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. Arthritis Res Ther 2014;16:1-7.
35. Lee YH, Bae SC. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2016;36:837-44.
36. Potter C, Cordell HJ, Barton A et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFkB signalling pathways. Ann Rheum Dis 2010;69:1315-20.
37. Sode J, Vogel U, Bank S et al. Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis. Pharmacogenomics J 2016; Advance Access published 4 October 2016, doi: 10.1038/tpj.2016.66.
38. Wang J, Bansal AT, Martin M et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J 2013;13:235-41.
39. Maldonado-Montoro M, Cañadas-Garre M, Gonzá lez-Utrilla A, Plaza-Plaza JC, Calleja-Herná ndez MÁ. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res 2016;111:264-71.
40. Schaeverbeke T, Truchetet ME, Kostine M et al. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology 2016;55:210-20.
41. Radstake TRDJ, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
42. Krintel SB, Grunert VP, Hetland ML et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology 2013;52:1245-53.
43. Murdaca G, Spano F, Contatore M et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Immunogenicity of infliximab and adalimumab?: what is its role in hypersensitivity and modulation of therapeutic efficac. Expert Opin Drug Saf 2016;15:43-52.
44. Pascual-Salcedo D, Plasencia C, Ramiro S et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50:1445-52.
45. Thomas SS, Borazan N, Barroso N et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs 2015;29:241-58.
46. Van Schouwenburg P, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164-72.
47. Bartelds GM, Wijbrandts CA, Nurmohamed MT et al. Antiinfliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and antitumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010;69:817-21.
48. Jamnitski A, Bartelds GM, Nurmohamed MT et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011;70:284-8.
49. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
50. Bartelds G, Krieckaert C, Nurmohamed M et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA Intern Med 2011;305:1460-8.
51. Smolen JS, Landewé R, Bijlsma J et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
52. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebocontrolled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
53. Mease P, Cohen S, Gaylis N et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 2010;37:917-27.
54. Boland BS, Sandborn WJ, Chang JT. Update on janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am 2014;43:603-17.
55. Leon L, Rodriguez-Rodriguez L, Rosales Z et al. Longterm drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol 2016;45:1-5.
56. Humphreys JH, Verstappen SM, Hyrich KL et al. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis 2013;72:1315-20.
57. Cho S, Sakai R, Nanki T, Koike R, Watanabe K. A comparison of incidence and risk factors for serious adverse events in rheumatoid arthritis patients with etanercept or adalimumab in Korea and Japan. Mod Rheumatol 2014;24:572-9.
58. Marchesoni A, Zaccara E, Gorla R et al. TNF-a antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009;1173:837-46.
59. Sakai R, Tanaka M, Nanki T et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Ann Rheum Dis 2012;72:1820-6.
60. Gäwert L, Hierse F, Zink A, Strangfeld A. How well do patient reports reflect adverse drug reactions reported by rheumatologists? Agreement of physician-and patienthttps reported adverse events in patients with rheumatoid arthritis observed in the German biologics register. Rheumatology 2011;50:152-60.
61. Naranjo A, Ojeda S, Francisco F et al. Fibromyalgia in patients with rheumatoid arthritis is associated with higher scores of disability. Ann Rheum Dis 2002;61:660-1.
62. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004;31:695-700.
63. Ranzolin A, Brenol JC, Bredemeier M et al. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:794-800.
64. Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A. Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity. Rheumatol Int 2014;34:1275-80.
65. Fan A, Tournadre A, Pereira B et al. Performance of Fibromyalgia Rapid Screening Tool (FiRST) to detect fibromyalgia syndrome in rheumatic diseases. Rheumatology 2016;55:1746-50.
66. Atzeni F, Cazzola M, Benucci M et al. Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract Res Clin Rheumatol 2011;25:165-71.
67. Wolfe F, Smythe H, Yunus M et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
68. Ton E, Bakker MF, Verstappen SM et al. Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis. J Rheumatol 2012;39:22-7.
69. Scott IC, Scott DL. Joint counts in inflammatory arthritis. Clin Exp Rheumatol 2014;32:S7-12.
70. Boyden SD, Hossain IN, Wohlfahrt A, Lee YC. Non-inflammatory causes of pain in patients with rheumatoid arthritis. Curr Rheumatol Rep 2016;18:30.
71. Mian AN, Chaabo K, Wajed J et al. Rheumatoid arthritis patients with fibromyalgic clinical features have significantly less synovitis as defined by power Doppler ultrasound. BMC Musculoskelet Disord 2016;17:404.
72. Lage-Hansen PR, Chrysidis S, Lage-Hansen M et al. Concomitant fibromyalgia in rheumatoid arthritis is associated with the more frequent use of biological therapy: a cross-sectional study. Scand J Rheumatol 2016;45:45-8.
73. Jurgens M, Overman C, Jacobs J et al. Contribution of the subjective components of the Disease Activity Score to the response to biological treatment in rheumatoid arthritis. Arthritis Care Res 2015;67:923-8.
74. Meijer JM, Meiners PM, Huddleston Slater JJ et al. Healthrelated quality of life, employment and disability in patients with Sjögren's syndrome. Rheumatology 2009;48:1077-82.
75. Romanowska-Prochnicka K, Olesinska M, Paradowska-Gorycka A et al. Discrepancies in assessment of patients with rheumatoid arthritis and secondary Sjögren's syndrome by DAS28-ESR and DAS28-CRP. Cent Eur J Immunol 2016;41:188-94.
76. George M, Baker JF. The obesity epidemic and consequences for rheumatoid arthritis care. Curr Rheumatol Rep 2016;18:6.
77. Sandberg MEC, Bengtsson C, Källberg H et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis 2014;73:2029-33.
78. Liu Y, Hazlewood G, Kaplan GG, Eksteen B, Barnabe C. The impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 2017;69:157-65.
79. Gremese E, Carletto A, Padovan M et al. Obesity and reduction of the response rate to anti-tumor necrosis factor a in rheumatoid arthritis: An approach to a personalized medicine. Arthritis Care Res 2013;65:94-100.
80. Gardette A, Ottaviani S, Sellam J et al. Body mass index and response to abatacept in rheumatoid arthritis. Eur J Clin Invest 2016;46:1048-52.
81. Pers YM, Godfrin-Valnet M, Lambert J et al. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J Rheumatol 2015;42:580-4.
82. Ajeganova S, Andersson ML, Hafströlm I. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res 2013;65:78-87.
83. Sparks J, Halperin F, Karlson JC, Karlson EW, Bermas BL. Impact of bariatric surgery on patients with rheumatoid arthritis. Arthritis Care Res 2015;67:1619-26.
84. Pawlotsky Y, Goasguen J, Guggenbuhl P et al. Sigma ESR: an erythrocyte sedimentation rate adjusted for the hematocrit and hemoglobin concentration. Am J Clin Pathol 2015;122:802-10.
85. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 2009;38:396-402.
86. Pasma A, van Spijker A, Hazes JMW, Busschbach JJV, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum 2013;43:18-28.
87. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014;(11):CD000011.
88. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol 2001;54:57-60.
89. Burkhart PV, Sabaté E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh 2003;35:207.
90. Hope H, Bluett J, Hyrich K, Cordingley L, Verstappen SM. Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient outcomes. RMD Open 2016;2:e000171.
91. Vlieland ND, Gardarsdottir H, Bouvy ML, Egberts TCG, van den Bemt BJF. The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology 2016;55:704-9.